Arkin, Steven

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors

Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine

Hemophilia Treatment and ResearchPlatelet Disorders and Treatments

Cited by 476

Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII

RECHT, M., NEMES, L., MATYSIAK, M., MANCO‐JOHNSON, M., LUSHER, J., SMITH, M., MANNUCCI, P., HAY, C., ABSHIRE, T., O’BRIEN, A., et al. (2009) · Haemophilia

Hemophilia Treatment and ResearchPlatelet Disorders and Treatments

Cited by 92

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Konkle, B. A., Stine, K., Visweshwar, N., Harrington, T. J., Leavitt, A. D., Giermasz, A., Arkin, S., Di Russo, G., Snyder, A., Woolfson, A., et al. (2019) · Blood

Hemophilia Treatment and ResearchVirus-based gene therapy research

Cited by 22